Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III maintenance pemetrexed or gemcitabine vs surveillance in elderly advanced NSCLC
2012-005520-15Phase 3Active
- Sponsor
- IFCT
- Start
- Apr 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of pemetrexed and gemcitabine in non-small cell lung cancer (NSCLC) (3 arms), sponsored by IFCT. Primary endpoint: Overall survival. Started Apr 2013; status: active.
02
Drugs
pemetrexedgemcitabine
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2012-005520-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-005520-15.